EUVIMEDEUVIMED entdecken
LeitlinieStudienprotokollOpen Access · CC BY 4.0

Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline

Zumao Cao iD, Yongbo Wang, Xiaoyu Zhang, Lei Zhang, Zhicong Zeng, Fengxia Lin iD, Hairong Wang, Jingyu Huang, Chong Zou, Zhengan Bi, Yinghui Jin iD, Hongcai Shang und 1 weitere

Clinical and Public Health Guidelines · 2026-04 · 3 (2)

DOI: 10.1002/gin2.70068 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Public Health Guidelines, online erschienen am 01.04.2026. Verfasst von Zumao Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Internal Medicine of Traditional Chinese Medicine of Ministry of Education and Beijing Beijing University of Chinese Medicine Beiji…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myocardial infarction (MI) remains a major global health burden, with percutaneous coronary intervention (PCI) as the primary revascularization strategy. However, complications such as no‐reflow, reperfusion injury and in‐stent restenosis persist, requiring adjunctive therapies. Traditional Chinese Medicine (TCM), especially blood‐activating and stasis‐resolving Chinese patent medicine (CPM), is increasingly used in MI management.

Objective

To develop a living clinical practice guideline for the perioperative use of CPMs in the perioperative period of PCI for MI, based on rigorous and transparent methodology.

Methods

The guideline followed the WHO Handbook for Guideline Development, methods for developing integrated Chinese–Western medicine guidelines, and the living guideline framework. It will be reported in accordance with the RIGHT‐TCM extension. Clinical questions and outcomes were framed, selected and rated through structured discussions with the Guideline Steering Committee and the Guideline Development Group. A systematic review and Bayesian network meta‐analysis will evaluate the efficacy and safety of CPM. The certainty of evidence will be assessed using the GRADE approach, and recommendations will be formulated via the Evidence‐to‐Decision framework, incorporating benefits, harms, evidence certainty, feasibility and costs. When new clinical studies are included and critical outcomes' combined effect demonstrates directional or magnitude changes, the consensus and guideline development groups will jointly decide on new updates.

Conclusion

By addressing key clinical uncertainties and leveraging real‐time evidence updates, the guideline aims to enhance patient outcomes and support clinicians in decision‐making. Trial Registration: Guideline Registration Number: PREPARE‐2024CN596

Schlagwörter

Stichwörter der Autor:innen

Chinese patent medicinesguidelinemyocardial infarctionpercutaneous coronary interventionprotocol

Autor:innen und Institutionen

  • Key Laboratory of Internal Medicine of Traditional Chinese Medicine of Ministry of Education and Beijing Beijing University of Chinese Medicine Beijing China.
  • Dongzhimen Hospital Beijing University of Chinese Medicine Beijing China.
  • Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan University Wuhan China.
  • Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences Beijing China.
  • Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical Sciences Beijing China.
  • Shenzhen Bao'an District Traditional Chinese Medicine Hospital Shenzhen China.

ORCID-Profile: Zumao Cao, Fengxia Lin, Yinghui Jin, Romina Brignardello-Petersen

Zitieren

APA

Cao, Z., Wang, Y., Zhang, X., Zhang, L., Zeng, Z., Lin, F., Wang, H., Huang, J., Zou, C., Bi, Z., Jin, Y., Shang, H., & Brignardello-Petersen, R. (2026). Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline. Clinical and Public Health Guidelines, 3(2). https://doi.org/10.1002/gin2.70068

Vancouver

Cao Z, Wang Y, Zhang X, Zhang L, Zeng Z, Lin F, et al. Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline. Clinical and Public Health Guidelines. 2026;3(2). doi:10.1002/gin2.70068

BibTeX
@article{Cao2026,
  author = {Cao, Zumao and Wang, Yongbo and Zhang, Xiaoyu and Zhang, Lei and Zeng, Zhicong and Lin, Fengxia and Wang, Hairong and Huang, Jingyu and Zou, Chong and Bi, Zhengan and Jin, Yinghui and Shang, Hongcai and Brignardello-Petersen, Romina},
  title = {Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline},
  journal = {Clinical and Public Health Guidelines},
  year = {2026},
  volume = {3},
  number = {2},
  doi = {10.1002/gin2.70068}
}
Kostenlos starten →